Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapyV. Trillet-Lenoir, C. Ewen, J. Green et al.|European Journal of Cancer|1993Cited by 545
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 studyMartin Hutchings, Pieternella J. Lugtenburg, Rogier Mous et al.|The Lancet|2021Cited by 337
Discovering dominant tumor immune archetypes in a pan-cancer censusAlexis J. Combes, Sima P. Porten, Adam B. Olshen et al.|Cell|2021Cited by 172
Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation DataMartin Hutchings, Pieternella J. Lugtenburg, Rogier Mous et al.|Blood|2020Cited by 64
European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphomaPier Luigi Zinzani, F. Morschhauser, Lionel Karlin et al.|Haematologica|2016Cited by 48